Anti-SLC30A8 / ZNT8 / Zinc transporter 8

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. SLC30A8 antibody detects Zinc transporter 8, a pancreatic beta-cell-specific membrane protein that mediates zinc transport into insulin secretory granules. Encoded by the SLC30A8 gene on chromosome 8q24.11, this transporter belongs to the solute carrier family 30 (SLC30), which regulates intracellular zinc homeostasis. Zinc transported by ZNT8 is essential for insulin crystallization, storage, and secretion, making this protein a key regulator of glucose metabolism and endocrine function.Structurally, ZNT8 is a 369-amino-acid multi-pass membrane protein of approximately 41 kilodaltons containing six transmembrane domains and a cytosolic C-terminus that mediates zinc ion transport driven by proton exchange. It localizes specifically to insulin granule membranes in pancreatic beta cells, where it sequesters zinc into vesicles, facilitating insulin hexamer formation and regulated exocytosis. ZNT8 expression is controlled by glucose and insulin signaling, reflecting its integration into metabolic feedback loops.The SLC30A8 antibody is widely used in endocrinology, diabetes, and metabolism research to study zinc transport, insulin secretion, and beta-cell physiology. Western blot analysis detects a 41 kilodalton band corresponding to ZNT8, while immunofluorescence reveals granular cytoplasmic staining restricted to pancreatic islets. This antibody provides an excellent tool for exploring beta-cell biology and identifying autoantibody targets in diabetes pathogenesis.Loss-of-function mutations in SLC30A8 reduce zinc transport activity and have been associated with altered diabetes risk. While some variants protect against type 2 diabetes by enhancing beta-cell resilience, others increase susceptibility by impairing insulin maturation and secretion. ZNT8 is also a major autoantigen in type 1 diabetes, with circulating autoantibodies serving as biomarkers for early disease detection. The SLC30A8 antibody enables detailed characterization of ZNT8 expression, localization, and immunogenicity in metabolic and autoimmune contexts. NSJ Bioreagents validates this antibody for its applications, ensuring reliable detection for pancreatic and metabolic research.